This cohort study assesses the association between changes in Centers for Medicare & Medicaid Services reimbursement policy and erythrocyte-stimulating agent drug labels with outcomes for patients undergoing hemodialysis.
This study assesses the relationship between low-density lipoprotein cholesterol levels achieved with statin treatment and cardiovascular events in patients with preexisting ischemic heart disease.
This study of a Danish natonwide cohort of patients with uncomplicated hypertension reports that antihypertensive treatment with a β-blocker may be associated with increased risks of perioperative major adverse cardiovascular events and all-cause mortality.
This retrospective cohort study found that Hodgkin lymphoma survivors are at high risk for cardiovascular diseases.
Among a cohort of older adults in the Health ABC Study, this study finds that food frequency questionnaire–assessed sodium intake was not associated with 10-year mortality, incident cardiovascular disease, or incident heart failure.
Rodriguez and colleagues examine the risk of incident cardiovascular events among participants with hypertension according to systolic blood pressure levels of 140 mm Hg or higher or 120 to 139 mm Hg relative to an SBP lower than 120 mm Hg. In his Invited Commentary, James expands on the importance of delivering the right care to the right patients.
Cheng et al conduct a meta-analysis to separately evaluate the effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and major cardiovascular events in patients with diabetes mellitus.
Carey et al compare the rate of cardiovascular events between older individuals whose partner dies with those of a matched control group of individuals whose partner was still alive on the same day.
Andersson et al assess the association of β-blocker treatment with major cardiovascular adverse events and all-cause mortality in patients with ischemic heart disease undergoing noncardiac surgery. Also see the invited commentary by Whelton and Bansal.
Smith et al compare the relative clinical cardiovascular safety of 2 commonly used oral estrogen drugs—conjugated equine estrogens and estradiol. Their case-control study compares cardiovascular event risk among 384 postmenopausal women aged 30 to 79 years using oral hormone therapy. Incident venous thrombosis was the primary clinical outcome.
Gershon et al assess the association of long-acting β-agonists and anticholinergics for chronic obstructive pulmonary disease (COPD) with the risk of hospitalizations and emergency department visits for cardiovascular events. An invited commentary by Woodruff follows.